Blog

One in ten Americans who are 65 and older suffer from Alzheimer’s dementia. It’s the 6th leading cause of death in the country, and it is a scourge worldwide. But little is known about what causes Alzheimer’s, and cures have been elusive. Dr. Verna Porter specializes in treating people with Alzheimer’s, and she remains optimistic.

Although our medical community continues to strain under the burden of COVID-19, there has been hope, determination and progress. Neurological diseases do not stop and neither have we at Pacific Neuroscience Institute.

New Studies Blue Earth Diagnostics FLC-219: (PDF): An Open-label, Single-arm, Single-dose, Prospective, Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases After Radiation Therapy (PURSUE) (NCT04410367) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma (NCT03463265) Orbus Therapeutics (PDF): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience ( PDF ): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma ( NCT03463265 ) Orbus Therapeutics ( PDF ): A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine...

Will & Cary Singleton Donate $40 Million to Pacific Neuroscience Institute’s Brain Health Center for Alzheimer’s Treatment & Research SANTA MONICA (July 7, 2020) –A $40 million donation from Will and Cary Singleton will support the Pacific Neuroscience Institute (PNI) Brain Health Center at Providence...

U.S. News & World Report highlights quality, specialty care Ten Providence Southern California hospitals and affiliated partners in Los Angeles and Orange counties earned recognition on July 28, 2020, from U.S. News & World Report. With approximately 415 acute care hospitals in California, the 10...

Find out about the new and ongoing neuroscience clinical trials at Pacific Neuroscience Institute, addressing difficult diseases such as brain tumors.

Neurodegenerative disease is a broad term for a range of conditions which mostly affect neurons in the human brain. Currently, 5 million Americans suffer from Alzheimer's disease; 1 million from Parkinson's disease; and 30,000 from Huntington's disease.